Updating the Clinical Progress of DK210 (EGFR), Fusing IL-10 With wtIL-2 to Prevent Toxicity & Enhance Potency

Time: 11:00 am
day: Conference Day One


  • Treating patients with cold tumors has already elicited potent peripheral immune activation leading to confirmed stable disease of stage 4 PDAC, and unconfirmed stable disease of patients with stage 4 CRC
  • Indicating DK210 (EGFR) has successfully blunted IL-2 inflammatory toxicity while retaining potent immunological activation and dramatically improved its therapeutic index
  • Outlining how responses stimulated in a predictive in vitro assay correlate with patient anti-tumor responses on therapy, suggesting the capacity to select patients that are most likely to respond